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Prevention of renal failure: The Malaysian experience. Re-
nal replacement therapy in Malaysia has shown exponential
growth since 1990. The dialysis acceptance rate for 2003 was
80 per million population, prevalence 391 per million popula-
tion. There are now more than 10,000 patients on dialysis. This
growth is proportional to the growth in gross domestic product
(GDP). Improvement in nephrology and urology services with
widespread availability of ultrasonography and renal pathology
has improved care of renal patients. Proper management of re-
nal stone disease, lupus nephritis, and acute renal failure has
decreased these as causes of end-stage renal disease (ESRD) in
younger age groups. Older patients are being accepted for dial-
ysis, and 51% of new patients on dialysis were diabetic in 2003.
The prevalence of diabetes is rising in the country (presently
7%); glycemic control of such patients is suboptimal. Thirty-
three percent of adult Malaysians are hypertensive and blood
pressure control is poor (6%). There is a national coordinating
committee to oversee the control of diabetes and hypertension
in the country. Primary care clinics have been provided with kits
to detect microalbuminuria, and ACE inhibitors for the treat-
ment of hypertension and diabetic nephropathy. Prevention of
renal failure workshops targeted at primary care doctors have
been launched, opportunistic screening at health clinics is being
carried out, and public education targeting high-risk groups is
ongoing. The challenge in Malaysia is to stem the rising tide of
diabetic ESRD.
End-stage renal disease (ESRD) is a major problem
in both developing and developed countries [1, 2]. In de-
veloped economies, the rising incidence of ESRD among
the elderly and diabetics is a major concern because it
increases the cost of care in a treatment modality that al-
ready consumes a disproportionate share of the health
care budget [3–5]. Renal replacement therapy (RRT)
uses 1% of the total health care budget in the United
States, 2% of the health budget in the UK for treating
0.075% of the population, and 1.5% of the health care
expenditure in France [accounting for 9.8% of the gross
domestic product (GDP)], treating 0.034% of the popula-
tion. In the developing world, the challenge facing health
care providers is prioritizing finite health care resources in
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the face of many competing demands. Costly technology-
dependent treatment programs such as RRT may not
have the same priority as broad-based community health
initiatives such as eradication of HIV/AIDS, malaria, and
water-borne infectious diseases [6]. Recently, outbreaks
of communicable diseases such as Severe Acute Respi-
ratory syndrome [7], which have a major impact on the
economy, further strained health care resources and un-
derlines the importance of good public health measures.
This will be at the expense of tertiary care services.
Malaysia is a country in Southeast Asia with a popula-
tion of 25 million. It is fortunate in being able to manage
community and public health problems well, as indicated
by such indices as maternal mortality rate (0.3 per 1000
live births) and infant mortality rate (6.3 per 1000 live
births) [8]. It was able to allocate considerable resources
to tertiary care services, including dialysis and renal trans-
plantation.
RENAL REPLACEMENT THERAPY
RRT in Malaysia has made considerable progress since
its modest beginnings in the late 1970s. Dialysis, partic-
ularly hemodialysis treatment, showed an almost expo-
nential growth. The new dialysis acceptance rate in the
year 2003 was 80 per million population, while the preva-
lence rate on December 31, 2003, was 391 [9] patients
per million per year (Figs. 1 and 2). There are now more
than 10,000 patients on dialysis in the country. The rapid
growth corresponded with the economic development of
the country (Fig. 3).
The demographics of new dialysis patients have
changed over the years, with increasing acceptance of
older patients in recent cohorts. A major concern has
been the trend where many of the new patients accepted
for RRT were diabetics [10]. In the year 2003, diabetes
mellitus was the cause of ESRD in 51% of all patients ac-
cepted for dialysis. The group classified as “unknown” has
decreased from a high of 81% in 1980 to 30% presently.
Although the exact diagnosis was not known, many in this
group were suspected to have glomerulonephritis based
on the clinical history and other findings.
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Year Fig. 1. New dialysis patients, Malaysia 1980to 2003.
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Fig. 2. Patients dialyzing in Malaysia on De-
cember 31, 1980 to 2003.
Despite these achievements, there are still many pa-
tients with renal failure in the country who are not
treated. The incidence of ESRD was estimated to be
86 per million population in 1991 [11]. It may be higher
because there are no community-based studies on inci-
dence of ESRD. The incidence in Singapore, an immedi-
ate neighbor, was higher, and was estimated to be 158 in
1997 [12].
PREVENTION OF RENAL FAILURE
INITIATIVES
In the past there has been no formal program in the
health care system in Malaysia that specifically focuses
on prevention of renal failure initiatives. Nonetheless,
efforts at improving the level of nephrology and urol-
ogy practices in the country over the last 20 years have
led to improved level of care and better outcomes in
many renal diseases. Such efforts include the training of
nephrologists and urologists and allied health care staff.
There were corresponding improvements in allied ser-
vices such as imaging studies, particularly the widespread
availability of ultrasonography, laboratory services, and
renal pathology.
Renal stone disease, which at one time was not an in-
frequent cause of morbidity and renal failure, has become
less of a problem partly due to the availability throughout
the country of lithotripsy machines and other less invasive
procedures to treat renal stones [13]. The management of
glomerular diseases has improved considerably with the
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Fig. 3. Dialysis prevalence rate per million population and gross domestic product (USD), Malaysia 1980 to 2003.
ready availability of renal biopsies and treatment regi-
mens that include the use of cytotoxics, plasmapheresis,
and dialysis for acute renal failure. This was reflected
in recent registry reports where the number of patients
with renal failure in the age group of 25 to 44 years has
declined over the years [10]. The management of lupus
nephritis with the judicious use of steroids and cytotox-
ics has led to better remission rates [14–16]. One hun-
dred and two systemic lupus erythmatosus (SLE) patients
in Kuala Lumpur were studied in 1996; 5-year and
10-year patient survival was 86% and 70%, respectively.
In 1984, Wang reported on 31 patients with membra-
nous lupus nephropathy with a 6-year survival of 50%
to 62%, depending on whether there was proliferation
in the glomeruli or not. In a group of 85 patients with
severe lupus nephritis (90% WHO class IV) reported in
2000 treated with intravenous cyclophosphamide, patient
survival was 75% at 5 years, and 64% at 10 years.
It is diabetes mellitus, however, that is causing con-
cern, and which has attracted the attention of health
care providers and clinicians alike. Apart from renal fail-
ure, the other well-known organ complications associ-
ated with diabetes are similarly stretching health care
resources in the country. The WHO has forecast that Asia
will have the highest number of diabetic patients by 2030
compared to other regions in the world [17]. The world
diabetic population is up from 171 million in 2000 to 194
million in 2003, and is estimated to reach 366 million by
2030.
Extrapolating from the second National Health and
Morbidity survey (NHMS) of 20,208 adults older than
30 years of age, in 1996 the prevalence of diabetes mel-
litus in the country was 7%, and the prevalence of im-
paired glucose tolerance was 5% [18]. The urban areas
had a higher prevalence than rural areas. Earlier studies
showed the prevalence to be increasing, and there was
a trend to increase prevalence as the population moves
from rural to urban areas [17, 19, 20]. In 1984, the preva-
lence was 4% in a study in Kuala Selangor, Malaysia, and
in 1986, the first NHMS reported the prevalence as 6.3%.
With development, there is increasing urbanization and
affluence, and the incidence of diabetes can be expected
to increase further. There will be more diabetic end-stage
renal failure in the future.
There was also a high prevalence of hypertension
among the adult population in the country [21]. In the
NHMS of 1996, 21,391 adults aged older than 30 years
were surveyed. Approximately 33% of people older than
30 years old (about 2.6 million people in Malaysia) have
hypertension. Of these, 23% have been prescribed med-
ication and only 6% were controlled. In a study of 926
diabetic patients from different centers in peninsular
Malaysia in 2000, mean HbA1c was 8.6%, and 61.1%
of patients had HbA1c greater than 8%. The control of
both hyperglycemia in diabetic patients and of the blood
pressure in hypertensive patients is, therefore, far from
satisfactory [22–24].
It is this realization of the high prevalence of diabetes
and hypertension and the poor glycemic and blood pres-
sure control that the Ministry of Health, together with
the professional societies such as the National Diabetes
Institute, the Malaysian Society of Hypertension, and the
Malaysian Society of Nephrology is embarking on a num-
ber of initiatives to control diabetes and hypertension and
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reduce the progression of renal failure. The initiatives also
extend to nondiabetic renal diseases.
Among the initiatives is the setting up of a national-
level coordinating committee to oversee the control of
diabetes and hypertension in the country. The commit-
tee consists of representatives from the public sector,
the universities, and professional societies. The commit-
tee formulated plans for screening of diabetes, diabetic
nephropathy, and other organ complications. It endorses
and disseminates clinical practice guidelines developed
by professional groups. It monitors the general trend in
diabetic care through a common data set developed for
the public sector. The primary care physician, both in
public and private sectors, has been identified as the key
personnel for this program, and all efforts are channeled
through the primary care clinics.
Diabetic nephropathy
In the public health care system, a common database
was developed to monitor treatment of diabetic patients
and track the development of complications, including
nephropathy. Patients carry a treatment card, which in-
corporates the data set, and doctors and their staff fill in
the appropriate entries at each encounter. An electronic
version is being developed. All government primary care
clinics are provided with kits to detect microalbuminuria.
The guidelines call for this test to be done yearly in dia-
betic patients who are negative for overt albuminuria [25,
26]. Diabetic patients have their renal function tested and
blood pressure taken at regular intervals. Angiotensin-
converting enzyme inhibitors (ACEI) are made available
in the most rural clinic, and patients that are ACEI intoler-
ant are prescribed angiotensin receptor blockers (ARBs)
after a review by the internal medicine specialist. HbA1c
test is now available in the smaller rural clinics. Most
classes of antihypertensives are available in these clin-
ics, as are the commonly used sulfonylureas, metformin,
and insulin.
Continuing education activities
“Prevention of renal failure” workshops are now be-
ing held across the country (since 2003), targeting pri-
mary care doctors and allied health care staff. The focus
is on the optimal management of diabetes and hyperten-
sion. The workshop also addresses screening for renal
disease and the management of nondiabetic renal dis-
eases. Five sessions have been done so far and two are in
planning with the plan to have these sessions regularly in
all Malaysian towns.
Public education activities
Ministry of Health Public Health Division, family
medicine specialists, and Malaysian Diabetes Association
have been holding public forums and screening work-
shops regularly for people with diabetes and family mem-
bers.
Through the Ministry of Health’s Healthy Lifestyle
Campaign, which began in 1991, diabetes mellitus was
the theme for the year 1996. The promotion of adopting
a healthy lifestyle for the prevention of diabetes by creat-
ing awareness of a balanced diet, maintaining ideal body
weight, and increasing physical activity was encouraged.
The campaign emphasized raising awareness of the dis-
ease and its complications to the public. Guidelines on
patient education were developed [20].
CONCLUSION
The incidence and prevalence of renal diseases leading
to ESRD is known in Malaysia, with the National Renal
Registry reporting for its 11th year. Instead of continuing
with increasing numbers of hemodialysis units and pa-
tients exponentially, a better way is to combat the disease
at an earlier stage. Screening and detection of diabetic
nephropathy is being done in primary care settings. Rais-
ing awareness of doctors and patients about the threat of
renal failure is ongoing. Population-based screening has
not been done on a coordinated scale. The prevalence
of chronic kidney disease in the community is unknown.
This may be incorporated as an objective of the third Na-
tional Health and Morbidity survey that is due in 2006.
The ultimate aim is to prevent illness, or else to prevent
the complications of illness. When will society reap the
benefits of prevention strategies and how it will be mea-
sured is still unknown. There are few data on the value
of screening for early renal disease and how to focus this
in order to ensure an optimum cost-benefit ratio.
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